Investor Type | Firm |
Type of Fund | VC |
Industries | BioTech • HealthTech (& Fitness) • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Mobile • Pharmaceutical (& Medicine) |
Stages | Seed, Startup, Early Stage, Expansion, Later Stage, Restructuring, Consolidation, PIPE, Going Private, Series A, Series B |
Investing | United States • United Kingdom • Germany • France • Sweden • Netherlands • Denmark • Europe |
Investment Range | $15,000,000 - $30,000,000 |
Investment Sweet Spot | $22,500,000 |
Assets Under Management | $1,800,000,000 |
Founded in 1973, Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors. The company invests across all stages of company development including early and late-stage venture financing, growth equity, and public companies. With offices in London, Boston and Menlo Park, Abingworth has backed more than 100 developing life science/medical businesses, over two-thirds of which have gone public, merged, or been acquired. Abingworth has funds under management of more than $1.25 billion. The firm has raised eleven funds since it was founded in 1973, the last nine of which have been entirely dedicated to life sciences and healthcare. Abingworth's investments are based in the U.S. and Europe including the U.K., Belgium, Denmark, France, Germany, Holland and Sweden. The firm's investments range from $20-80 million over more than one round of financing. In February 2014, the firm announced the final closing of its POUND 225M ($375M) fund, Abingworth Bioventures VI (ABV VI). ABV VI is Abingworth's 10th life sciences fund.